Table 1.
Study population characteristics grouped by CYP3A4/5 combined genotype.
| Poor metabolizers |
Intermediate metabolizers |
Extensive metabolizers |
|
|---|---|---|---|
| Number | 19 (8%) | 167 (71%) | 49(21%) |
| Atorvastatin dose (n=142) | 20 (10,20) | 20(10,40) | 20 (20,40) |
| Simvastatin dose (n=84) | 20 (10,40) | 40 (20,40) | 40 (20,40) |
| Lovastatin dose (n=9) | 20 (20,20) | 20(20,40) | −(−,−) |
| Combined dose (n=235)a | 16.6 (10,20) | 23.2(16.6,40) | 33.2(16.6,40) |
| Age | |||
| Combined (all three statins) | 64±12 | 63±11 | 5 6±9 |
| Male | |||
| Combined (all three statins) | 13(8%) | 113 (72%) | 32 (20%) |
| Caucasian | |||
| Combined (all three statins) | 19 (9%) | 160 (77%) | 29 (14%) |
Data for age are mean±SD. Data for number, race, and gender represent number and percentage. Data for dose represent the median (first quartile, third quartile) for each metabolizer group and statin type.
a
Combined statin dose was calculated by first determining an atorvastatin-equivalent dose for simvastatin and lovastatin (i.e., simvastatin and lovastatin have 83% and 58% the potency, respectively, of atorvastatin [5]).